The new drug is the first FDA-approved option for this indication in more than 15 years and contains significantly less sodium than a current standard-of-care option.
The US Food and Drug Administration has approved tofacitinib for the treatment of active polyarticular course juvenile idiopathic arthritis among pediatric patients aged 2 years or older.
The US Food and Drug Administration has approved tofacitinib for the treatment of active polyarticular course juvenile idiopathic arthritis among pediatric patients aged 2 years or older.
The US Food and Drug Administration has approved tofacitinib for the treatment of active polyarticular course juvenile idiopathic arthritis among pediatric patients aged 2 years or older.
The FDA has approved a treatment option for adults with multidrug resistant HIV infection, marking a “new class of antiretroviral medications” for this patient population.
The FDA has approved a treatment option for adults with multidrug resistant HIV infection, marking a “new class of antiretroviral medications” for this patient population.
The FDA has approved a treatment option for adults with multidrug resistant HIV infection, marking a “new class of antiretroviral medications” for this patient population.
The FDA has approved a drug therapy to treat seizures associated with Dravet syndrome–a chronic, rare, and life-threatening form of epilepsy–among patients aged 2 years or older.
The FDA has approved a drug therapy to treat seizures associated with Dravet syndrome–a chronic, rare, and life-threatening form of epilepsy–among patients aged 2 years or older.
The FDA has approved a drug therapy to treat seizures associated with Dravet syndrome–a chronic, rare, and life-threatening form of epilepsy–among patients aged 2 years or older.
